The report covers 2024 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy and RNA products
STUTTGART, Germany I March 09, 2025 I La Merie Publishing announced the release of its newest biologics market report for the calendar year 2024 covering individual sales data for nearly 400 biologic products. The report “2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA” analyzes market volume and growth rates of innovator, branded therapeutic antibodies and proteins and biosimilars of antibodies and proteins with loss of exclusivity. The report also describes the different market growth of the novel biologic drug modalities gene therapy, cell therapy and RNA therapy.
The combined market volume of innovator recombinant therapeutic antibodies and proteins continued its growth beyond the US$ 300 bln threshold. The market share of antibodies is getting closer to 90% as rarely new therapeutic proteins recently have been developed and approved except neuromodulators (botulinumtoxins) while established proteins continue to loose sales.
Erosion of sales of established therapeutic antibodies in favor of biosimilar antibodies continues while at the same time the market for established targets, e.g Her2, is growing due to innovations by novel drug modalities, such as antibody drug conjugates (ADCs) and bispecific antibodies. The report describes market volume and growth of ADCs and of bispecific antibodies.
The report also provides insight into therapeutic areas with highest market volumes and growth. Despite the tremendous erosion of the anti-TNF antibody market, innovative non-TNF anti-inflammatory antibodies more than compensate the anti-TNF antibody market erosion. The market of anti-inflammatory antibodies outperformes that of cancer antibodies and is by far higher than the market of ophthalmic and cardiometabolic antibodies. The report provides target-specific sales volumes for cancer antibodies and for anti-inflammatory antibodies.
A ranking list for blockbuster biologics, i.e. antibodies and proteins, is presented with 75 biologic products of more than US$ 1 bln in 2024 sales. Further ranking lists describe innovator biologics sales of major biopharmaceutical companies and biosimilar antibody and protein sales in 2024.
Methodology
The report covers sales data of nearly 400 commercialized biologics with 36 products included for the first time. Sales data were obtained from company disclosures and refer to innovative branded products as well as biosimilars and other biologics (gene & cell therapy, antisense, siRNA). All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of January 30, 2025. Cut-off date for inclusion into the report was March 06, 2025. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates are presented as reported, except in very few cases as constant exchange rates. All sales data refer to the calendar year 2024. Financial years differing from the calendar year were recalculated to the calendar year 2024 by summing up the respective calendar year quarterly sales.
The report 2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA can be acquired at La Merie Publishing’s online store www.lamerie.com: https://lamerie.com/report/2024-sales-of-therapeutic-antibodies-proteins-biosimilars-gene-cell-therapy-and-therapeutic-rna/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 264
The report covers 2024 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy and RNA products
STUTTGART, Germany I March 09, 2025 I La Merie Publishing announced the release of its newest biologics market report for the calendar year 2024 covering individual sales data for nearly 400 biologic products. The report “2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA” analyzes market volume and growth rates of innovator, branded therapeutic antibodies and proteins and biosimilars of antibodies and proteins with loss of exclusivity. The report also describes the different market growth of the novel biologic drug modalities gene therapy, cell therapy and RNA therapy.
The combined market volume of innovator recombinant therapeutic antibodies and proteins continued its growth beyond the US$ 300 bln threshold. The market share of antibodies is getting closer to 90% as rarely new therapeutic proteins recently have been developed and approved except neuromodulators (botulinumtoxins) while established proteins continue to loose sales.
Erosion of sales of established therapeutic antibodies in favor of biosimilar antibodies continues while at the same time the market for established targets, e.g Her2, is growing due to innovations by novel drug modalities, such as antibody drug conjugates (ADCs) and bispecific antibodies. The report describes market volume and growth of ADCs and of bispecific antibodies.
The report also provides insight into therapeutic areas with highest market volumes and growth. Despite the tremendous erosion of the anti-TNF antibody market, innovative non-TNF anti-inflammatory antibodies more than compensate the anti-TNF antibody market erosion. The market of anti-inflammatory antibodies outperformes that of cancer antibodies and is by far higher than the market of ophthalmic and cardiometabolic antibodies. The report provides target-specific sales volumes for cancer antibodies and for anti-inflammatory antibodies.
A ranking list for blockbuster biologics, i.e. antibodies and proteins, is presented with 75 biologic products of more than US$ 1 bln in 2024 sales. Further ranking lists describe innovator biologics sales of major biopharmaceutical companies and biosimilar antibody and protein sales in 2024.
Methodology
The report covers sales data of nearly 400 commercialized biologics with 36 products included for the first time. Sales data were obtained from company disclosures and refer to innovative branded products as well as biosimilars and other biologics (gene & cell therapy, antisense, siRNA). All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of January 30, 2025. Cut-off date for inclusion into the report was March 06, 2025. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates are presented as reported, except in very few cases as constant exchange rates. All sales data refer to the calendar year 2024. Financial years differing from the calendar year were recalculated to the calendar year 2024 by summing up the respective calendar year quarterly sales.
The report 2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA can be acquired at La Merie Publishing’s online store www.lamerie.com: https://lamerie.com/report/2024-sales-of-therapeutic-antibodies-proteins-biosimilars-gene-cell-therapy-and-therapeutic-rna/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 264
